Royal Bank of Canada
MDCX

Royal Bank of Canada’s Medicus Pharma MDCX Stock Holding History

Royal Bank of Canada’s Portfolio MDCX Stock Details MDCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,100
Closed -$42K – 7343
2024
Q4 		$42K Buy
+17,100
New +$43.4K ﹤0.01% 5780

Other funds holding MDCX

ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
PIMG
Patriot Investment Management Group Knoxville, Tennessee $1.72B AUM 17.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BWM
Base Wealth Management Lakewood Ranch, Florida $215M AUM 19.13% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada's MDCX Position: Q1 2025 in Review

Royal Bank of Canada sold out of Medicus Pharma (MDCX) in Q1 2025, closing a stake of 17,100 shares — an estimated $42K sold.

Royal Bank of Canada first reported a position in MDCX in Q4 2024 and held it in 1 quarter. The position peaked at $42K in Q4 2024. 7 funds tracked by Wall St. Rank hold MDCX as of Q1 2025.

  • Royal Bank of Canada reported no remaining Medicus Pharma position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 17,100 Medicus Pharma shares in Q1 2025, an estimated $42K.
  • Royal Bank of Canada first reported a position in Medicus Pharma in Q4 2024 and held it in 1 quarter.
  • Royal Bank of Canada's Medicus Pharma position peaked at $42K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Medicus Pharma as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.